SCHEMBL24437327

SCHEMBL24437327

COc1c(F)cc(NC2=CC(=O)N(c3ccccc3)C2=O)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 10/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ MAPT P10636 6/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ POLB P06746 2/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ NR1H3 Q13133 1/20 0.38
▸ HPGD P15428 6/20 0.37
▸ LMNA P02545 2/20 0.36
▸ IDO1 P14902 1/20 0.35
▸ MAPK1 P28482 1/20 0.34
▸ ICMT O60725 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205883 0.86 MEN1 (0.41) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL26205804 0.86 MEN1 (0.49) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL24437413 0.85 MEN1 (0.51) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL24430024 0.85 MEN1 (0.40) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL24430013 0.83 MEN1 (0.49) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL26205811 0.81 KMT2A (0.50) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL26205848 0.79 ALDH1A1 (0.54) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL26205908 0.79 MEN1 (0.48) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL26205906 0.79 KMT2A (0.45) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL26205826 0.79 MEN1 (0.52) MEN1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
WO-2022109066-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885ALDH1A1 703/4885
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 MEN1 4171/4885KMT2A 2088/4885ALDH1A1 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback